ReposiTrak offers a cash-rich, high-margin SaaS traceability platform whose near-term growth pause may be masking a powerful 2028 regulatory adoption cycle.
ReposiTrak, Inc. (NYSE: TRAK), operating historically as Park City Group, Inc. [1], provides a cloud-based Software-as-a-Service (SaaS) platform designed to enable retailers, wholesalers, distributors, and food manufacturers to manage regulatory compliance, food safety, and retail supply chain logistics.[2, 3] For the third quarter of fiscal 2026, ended March 31, 2026, the company reported total revenue of $5.88 million, representing a minor year-over-year decline of 0.52% compared to $5.91 million in the third quarter of fiscal 2025.[4, 5] This flat top-line performance was driven by a temporary deceleration in traceability onboarding volumes, which fell relative to a 16% onboarding surge in the prior-year period.[6] This shift occurred as a direct consequence of the federal extension of the Food Safety Modernization Act Section 204 (FSMA 204) compliance deadline.[6]
Despite near-term revenue stagnation, ReposiTrak demonstrated substantial operating leverage.[4] Third-quarter operating expenses declined by 11.52% to $3.63 million, primarily due to a reduction in depreciation and amortization expenses to $95,414 from $328,723 in the prior-year quarter.[4, 5] This reduction pushed quarterly operating income up by 24.46% to $2.25 million, yielding an operating margin of 38.27%.[4, 5] GAAP net income rose 1.01% to $1.99 million.[4, 5] For the nine months ended March 31, 2026, cumulative revenue increased by 5.14% to $17.71 million, cost of revenue declined by 9.45% to $2.51 million, and operating income expanded by 28.47% to $5.96 million.[4, 5]
| Financial Metric | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 | YoY Change (%) | Nine Months Ended March 31, 2026 | Nine Months Ended March 31, 2025 | YoY Change (%) |
|---|---|---|---|---|---|---|
| Total Revenue | $5,883,198 | $5,913,732 | -0.52% | $17,711,476 | $16,845,782 | +5.14% |
| Cost of Rev. & Product Support | $803,353 | $911,693 | -11.88% | $2,511,249 | $2,773,468 | -9.45% |
| Sales & Marketing | $1,356,865 | $1,408,861 | -3.69% | $4,458,676 | $4,392,997 | +1.50% |
| General & Administrative | $1,376,346 | $1,455,602 | -5.44% | $4,216,435 | $4,124,706 | +2.22% |
| Depreciation & Amortization | $95,414 | $328,723 | -70.97% | $563,090 | $913,646 | -38.37% |
| Total Operating Expenses | $3,631,978 | $4,104,879 | -11.52% | $11,749,450 | $12,204,817 | -3.73% |
| Income from Operations | $2,251,220 | $1,808,853 | +24.46% | $5,962,026 | $4,640,965 | +28.47% |
| GAAP Net Income | $1,985,635 | $1,965,788 | +1.01% | $5,491,204 | $5,182,023 | +5.97% |
| Preferred Stock Dividends | $34,285 | $85,725 | -59.99% | $139,653 | $289,223 | -51.71% |
| Net Income to Common Holders | $1,951,350 | $1,880,063 | +3.79% | $5,351,551 | $4,892,800 | +9.38% |
| Diluted EPS (Common) | $0.10 | $0.10 | 0.00% | $0.28 | $0.26 | +7.69% |
Source: SEC Form 10-Q filed May 14, 2026 [4, 5]
The core investment thesis is anchored on three main factors. First, over 98% of total revenue is derived from recurring SaaS contracts [4], presenting high visibility and a structural net margin exceeding 30%.[4, 7] Second, the systematic redemption of Series B Preferred Stock continues to eliminate the preferred dividend obligation, which declined 51.71% year-to-date.[5] This cash flow redirection expands net income applicable to common shareholders and structurally drives EPS growth.[5] Third, the company's strategic alliance with SPAR Group, Inc. (NASDAQ: SGRP)—established through a $3.00 million promissory note and a 14.8% beneficial equity ownership stake—pairs ReposiTrak’s upstream compliance software with SPAR’s physical, in-store merchandising execution.[5, 8, 9]
ReposiTrak’s platform operates across three principal product suites: food traceability, compliance and risk management, and supply chain solutions.[10] The company’s long-term business strategy has focused on migrating away from high-touch, low-margin professional services and scan-based trading (SBT) legacy platforms to build a standardized, recurring subscription model.[2, 7] Since fiscal 2020, management has converted more than $7.00 million of historical, one-time revenue into recurring SaaS contracts, while deliberately eliminating approximately $2.00 million of low-margin revenue lines.[7] Consequently, recurring revenue has risen to more than 98% of total revenue, up from 62% in fiscal 2020.[7]
| Compliance & Risk Management | Food Traceability (RTN) | Supply Chain & SBT Solutions |
|---|---|---|
| • Supplier document management [2] | • Key Data Element (KDE) capture [11] | • Scan-based trading (SBT 2.0) [11] |
| • Sourcing and supplier vetting [12] | • Critical Tracking Event validation [11] | • Out-of-stock management [2] |
| • Automated brand protection [10, 13] | • Touchless Traceability™ integration [14] | • Inventory order optimization [2] |
Source: SEC Form 10-K and Corporate Materials [2, 11, 13, 14]
The primary long-term operational driver is the ReposiTrak Traceability Network (RTN), which has collected more than 8.2 million supplier compliance records.[3, 15] Under the FDA’s FSMA 204 guidelines, food supply chain participants must maintain electronic tracking records of Key Data Elements (KDEs) for certain Critical Tracking Events (CTEs) across specific items on the Food Traceability List (FTL).[11, 16] This regulatory environment transforms compliance from a basic administrative check into an active operational data challenge for suppliers who lack standardized technology infrastructure.[16, 17]
To solve this friction point, ReposiTrak introduced its patent-pending Touchless Traceability™ technology.[13, 14] This application ingests raw supplier shipment data in any legacy transmission standard (such as EDI, CSV, XML, or JSON), automatically identifies data structure anomalies, and applies rules-based, AI-driven corrections to generate compliant KDE records without requiring capital investments in warehouse hardware or case-level scanning.[3, 14] By acting as a shared system of record [3, 18], ReposiTrak drives network effects: once a major retailer mandates compliance via the RTN, its entire upstream supplier ecosystem is onboarded onto the platform, expanding the paid endpoint base.[3, 19] The platform currently represents more than 8% of all retail supermarkets in the United States.[20]
This database is supported by key contract wins, including Erewhon (selected April 2026) [21], Piggly Wiggly Alabama Distributing Company (selected June 2026) [11, 14], and long-standing compliance partnerships with major organizations like SpartanNash, World Food Products, and The H&H Group.[11, 19, 21]
A major strategic pivot occurred on March 16, 2026, when ReposiTrak’s subsidiary, PC Group, Inc., entered into a strategic commercial alliance with SPAR Group, Inc..[9] ReposiTrak funded a Senior Unsecured Promissory Note with SPAR Marketing Force, Inc. for an aggregate principal amount of up to $4.00 million, consisting of an initial $3.00 million advance and an additional $1.00 million tranche available starting July 17, 2026.[9] The note bears interest at 8.0% per annum (payable monthly, interest-only) and matures on March 16, 2029.[9]
In connection with this loan, SPAR Group issued 1,000,000 common shares to PC Group.[9] Subsequently, on May 29, 2026, SPAR Group amended its services agreement, allowing ReposiTrak to choose stock payment to settle outstanding receivables.[22] ReposiTrak chose stock settlement, resulting in the issuance of 3,190,569 common shares of SPAR Group to satisfy a $2,325,000 service-related payable, valued at a deemed price of $0.7287 per share.[8, 22] This brought ReposiTrak’s beneficial ownership to 4,190,569 shares, representing a 14.8% equity stake in SPAR Group.[8]
This structural alliance connects ReposiTrak’s digital supply chain and compliance software with SPAR Group's physical, in-store retail merchandising operations, creating a closed-loop platform that can identify supply chain anomalies digitally and resolve them physically on retail shelves.[4, 5]
ReposiTrak’s financial architecture is characterized by strong operating margins, cash generation, and a conservative capital structure.[4, 7] For the nine months ended March 31, 2026, the company generated $5.86 million in cash from operations, down from $6.76 million in the prior-year period.[5] This decrease was primarily driven by working capital adjustments, including an increase in net accounts receivable to $5.10 million from $4.13 million.[5]
Non-cash adjustments to net income included a bad debt provision of $675,000 and depreciation and amortization of $563,090, which fell 38.37% year-over-year.[4, 5] The balance sheet remains clean with no bank debt [4] and $26.41 million in cash and cash equivalents.[5]
| Balance Sheet Component | March 31, 2026 | June 30, 2025 | Absolute Change | Percentage Change |
|---|---|---|---|---|
| Cash and Cash Equivalents | $26,409,558 | $28,568,805 | -$2,159,247 | -7.56% |
| Receivables, net | $5,101,465 | $4,133,026 | +$968,439 | +23.43% |
| Contract Asset (Current Portion) | $454,408 | $428,585 | +$25,823 | +6.02% |
| Prepaids & Other Current Assets | $1,137,554 | $555,384 | +$582,170 | +104.82% |
| Total Current Assets | $33,102,985 | $33,685,800 | -$582,815 | -1.73% |
| Notes Receivable (SPAR) | $3,000,000 | $0 | +$3,000,000 | New Asset |
| Goodwill | $20,883,886 | $20,883,886 | $0 | 0.00% |
| Capitalized Software Costs, net | $0 | $128,207 | -$128,207 | -100.00% |
| Total Assets | $57,375,711 | $55,329,047 | +$2,046,664 | +3.70% |
| Accounts Payable & Accrued Liab. | $2,777,664 | $2,123,985 | +$653,679 | +30.78% |
| Contract Liability (Deferred Rev.) | $3,754,750 | $3,175,908 | +$578,842 | +18.23% |
| Total Current Liabilities | $6,766,937 | $5,531,118 | +$1,235,819 | +22.34% |
| Total Liabilities | $6,881,876 | $5,809,866 | +$1,072,010 | +18.45% |
| Series B Preferred Stock | $1,609 | $3,361 | -$1,752 | -52.13% |
| Common Stock | $181,738 | $182,830 | -$1,092 | -0.60% |
| Accumulated Deficit | -$8,701,405 | -$12,836,910 | +$4,135,505 | -32.22% |
| Total Stockholders' Equity | $50,493,835 | $49,519,181 | +$974,654 | +1.97% |
Source: SEC Form 10-Q filed May 14, 2026 [5]
A key focus of ReposiTrak's capital allocation is the ongoing redemption of its Series B Preferred Stock.[5, 13] This preferred stock carries a par value of $0.01 but a redemption value of $10.70 per share.[5, 6] In the third quarter of fiscal 2026, the company redeemed 35,047 preferred shares for $375,000 [4, 6], leaving 160,865 preferred shares outstanding on March 31, 2026.[5, 6]
Since inception, the company has redeemed a total of preferred shares (including both Series B and fully retired Series B-1) for a total of $7.30 million [6], with $1.70 million remaining under the current redemption authorization.[6] At the current redemption rate, the company expects to retire all remaining preferred shares on or before September or December 2026.[5, 13] This retirement will eliminate approximately $140,000 in annualized preferred dividend obligations, allowing these funds to flow directly to common EPS.[5]
Simultaneously, the company returned capital through common share buybacks.[4] During the third quarter of fiscal 2026, the company repurchased and cancelled 55,262 common shares for $550,000 at an average price of $9.95 per share.[4, 6] For the first nine months of the fiscal year, common stock repurchases reached 144,000 shares for a total of $1.80 million at an average price of $12.50 per share.[7] Since inception, ReposiTrak has repurchased and cancelled 2.22 million common shares for $14.50 million at an average price of $6.52 per share.[23] This leaves approximately $6.00 million remaining under the $21.00 million total buyback authorization.[6]
Additionally, the board declared a quarterly cash dividend of $0.02 per share ($0.08 annualized), which was paid on May 15, 2026, to shareholders of record on March 31, 2026.[4, 6] This dividend has grown at a compound annual rate of 10% for three consecutive years since September 2022.[7, 13]
| Financial Metric | Metric Value | Analytical Relevance |
|---|---|---|
| Trailing P/E Ratio | 24.86x [24] | Trades below the US Software industry average of 28.50x.[25] |
| Price/Book Ratio | 3.31x [24, 26] | Reflects a lean capital structure with significant asset backing. |
| Cash per Share | $1.45 [26] | Represents approximately 15.8% of the current market share price. |
| Remaining Buyback Authorization | $6.00 Million [6] | Provides solid downside support in periods of market volatility.[6, 23] |
| Stated Preferred Redemption Price | $10.70 [6] | Stated price for the final retirement of Series B Preferred shares.[5] |
| Expected Corporate Tax Rate | 20.00% [7] | Long-term modeling assumption for net income calculations. |
Source: SEC Form 10-Q and Financial Database [6, 7, 24, 25, 26]
From a valuation perspective, ReposiTrak’s trailing P/E of 24.86x [24] is below the peer average of 25.2x and the U.S. application software average of 28.5x.[25] This discount is notable given the company's 30.15% profit margin [26] and recurring revenue model.[4] The market’s valuation appears to discount the near-term revenue slowdown from the FSMA 204 extension [6], presenting an attractive valuation entry point relative to its long-term cash flow profile.[25, 27]
The regulatory landscape is the primary driver of volatility for ReposiTrak.[15] Under the Congressional directive in the Continuing Appropriations Act of 2026 and the subsequent FDA Federal Register notice, the official enforcement deadline for FSMA 204 was extended by 30 months from January 20, 2026, to July 20, 2028.[16, 28] This timeline shift has reduced the immediate compliance pressure on regional and mid-sized food suppliers.[17] While tier-1 distributors are still enforcing private compliance targets, smaller operators are deferring platform enrollment to preserve capital.[16, 17] This delay is the primary reason behind the flat year-over-year revenue reported in Q3 fiscal 2026.[6]
| Market Participant Group | 2025 Market Share (%) |
|---|---|
| SAP SE (Market Leader) | 8.5% [29] |
| Top 5 Consolidated Players (SAP, Zebra, Honeywell, ReposiTrak, IBM) | 41.7% [29] |
| Fragmented Tail Competitors (e.g., FoodLogiQ, rfxcel, iFoodDS, Trimble) | 58.3% [29, 30] |
Source: Global Market Insights [29, 30]
Competitive pressure remains an ongoing concern in the growing food traceability sector.[29] The global food traceability solutions market reached $28.80 billion in 2026 and is projected to reach $64.50 billion by 2035.[29] The global FSMA 204 platform market segment alone was valued at $2.80 billion in 2025 and is projected to expand to $8.10 billion by 2034, registering a CAGR of 12.50%.[30] Within this market, software platforms hold a 48.3% share, hardware holds 29.4%, and services make up 22.3%.[30]
ReposiTrak faces direct competition from larger enterprise resource planning (ERP) systems, hardware integrators, and niche B2B software vendors.[2, 29] Many of these competitors possess substantially larger sales operations and marketing budgets.[2] A key competitive risk is the potential for larger players to bundle compliance modules into existing ERP packages, which could pressure ReposiTrak's market share or pricing power.[2, 25]
Furthermore, ReposiTrak has customer concentration in its accounts receivable.[2] One customer accounted for more than 10% of total accounts receivable as of June 30, 2025, and June 30, 2024, with an outstanding balance of $962,300 in both periods.[2] Financial distress, contract termination, or pricing renegotiations by this client could impact the company's working capital.
ReposiTrak also faces counterparty risk through its SPAR Group transaction.[8, 9] SPAR Group is currently undergoing a structural turnaround and received a Nasdaq non-compliance notice because its stock price fell below the $1.00 minimum bid requirement.[31] To maintain its listing, SPAR Group is planning a 1-for-5 reverse stock split.[31] ReposiTrak has direct exposure to SPAR Group through its $3.00 million promissory note and its 14.8% beneficial equity ownership.[5, 8]
Finally, macroeconomic factors like declining interest rates present a risk to interest income, which grew to $1.08 million for the nine months ended March 31, 2026.[5] This interest rate sensitivity is highlighted by the $128,697 unrealized loss on short-term investments recorded in Q3 fiscal 2026.[5]
To evaluate ReposiTrak’s long-term financial path through the July 2028 FSMA 204 enforcement deadline, a five-year projection model was built.[16, 32] Revenue is projected using a standard compound growth rate model:
$Rev_{t} = Rev_{0} \times (1 + g)^t$
Diluted EPS is projected using the following formula:
$Diluted\ EPS_{t} = \frac{(Rev_{t} \times OM_{t}) + Interest\ Income_{t} - Taxes_{t} - Preferred\ Dividends_{t}}{Diluted\ Shares_{common, t}}$
Where $OM_{t}$ is the projected operating margin, $Interest\ Income_{t}$ is modeled at 4.5% of the cash balance plus interest from the SPAR note [5, 9], $Taxes_{t}$ is modeled at a standard 20% corporate rate [7], $Preferred\ Dividends_{t}$ is modeled to go to zero by fiscal 2027 following full redemption [5], and $Diluted\ Shares_{common, t}$ is modeled to decline by 1% annually through share buybacks.[7, 23] The model uses fiscal year 2025 revenue of $22.61 million as its base.[33]
| Projection Variable | Year 1 (FY 2026) | Year 2 (FY 2027) | Year 3 (FY 2028) | Year 4 (FY 2029) | Year 5 (FY 2031) | 5-Year CAGR (%) |
|---|---|---|---|---|---|---|
| Base Case Revenue ($M) | $23.60 | $26.00 | $29.90 | $35.00 | $42.00 | +12.22% |
| Base Case Operating Margin (%) | 33.80% | 35.50% | 38.00% | 40.50% | 43.00% | N/A |
| Base Case Common EPS ($) | $0.37 | $0.44 | $0.55 | $0.68 | $0.85 | +18.09% |
| Bull Case Revenue ($M) | $24.20 | $28.50 | $36.00 | $45.00 | $58.00 | +19.10% |
| Bull Case Operating Margin (%) | 34.50% | 38.00% | 42.00% | 45.00% | 48.00% | N/A |
| Bull Case Common EPS ($) | $0.39 | $0.52 | $0.75 | $1.02 | $1.42 | +29.50% |
| Bear Case Revenue ($M) | $23.10 | $23.80 | $24.50 | $26.00 | $28.50 | +4.29% |
| Bear Case Operating Margin (%) | 31.00% | 31.50% | 32.00% | 33.00% | 34.00% | N/A |
| Bear Case Common EPS ($) | $0.35 | $0.36 | $0.39 | $0.43 | $0.49 | +6.97% |
Source: Analytical Projections [7, 21, 32, 33, 35]
To evaluate the qualitative parameters of the ReposiTrak business model, the company is evaluated across six strategic pillars [2, 4, 8]:
| Strategic Pillar | Score (1-10) | Analytical & Qualitative Justification |
|---|---|---|
| SaaS Quality & Predictability | 9 / 10 | Over 98% recurring SaaS revenue, combined with an 81.6% gross margin and 30.1% net profit margin, provides high cash flow predictability.[4, 26] |
| Competitive Moat & IP Moat | 8 / 10 | Network effects are supported by patent applications for Touchless Traceability™, which simplifies onboarding for legacy suppliers.[13, 14] |
| Regulatory Risk Exposure | 7 / 10 | Although the FSMA 204 delay to July 2028 impacted near-term onboarding volumes, the underlying regulation remains a long-term catalyst.[16, 17] |
| Capital Allocation Execution | 9 / 10 | Solid capital allocation is demonstrated through preferred stock redemptions, common stock buybacks, and 10% annual dividend growth.[6, 7] |
| Strategic Partner Risk | 5 / 10 | The 14.8% stake in SPAR Group offers synergy potential but carries risk due to SPAR's current turnaround status and Nasdaq non-compliance.[8, 31] |
| Management Alignment | 10 / 10 | CEO Randall Fields directly owns 21.56% of outstanding common shares, aligning management's interests with common shareholders.[36, 37] |
| Total Weighted Score | 8.00 / 10 | Indicates a structurally sound company with solid alignment, though offset by regulatory timing and counterparty risks.[6, 8, 36] |
Source: Analyst evaluations [4, 8, 13, 16, 36]
The qualitative and quantitative data suggests a favorable long-term outlook for ReposiTrak, Inc..[4, 17] While the flat year-over-year revenue in Q3 fiscal 2026 has impacted short-term momentum, it reflects a temporary timing issue rather than structural weakness.[6] The 30-month extension of the FSMA 204 deadline to July 2028 has shifted the onboarding curve outward, but the underlying regulatory requirement remains a long-term driver for the platform.[16, 17]
The investment thesis rests on three core pillars:
The 14.8% equity stake in SPAR Group introduces counterparty risk given SPAR's turnaround status.[8, 31] However, the strategic notes receivable yields a steady 8% cash-only return, and the commercial partnership could help the company bridge the gap between digital inventory tracking and physical in-store retail execution.[5, 9]
The stock’s trailing P/E of 24.86x [24] is below the application software industry average of 28.5x [25], and the estimated DCF fair value of $11.72 suggests potential undervaluation.[25] This valuation gap, combined with the one-year average target price of $16.00 to $16.32 [24, 38], presents an attractive long-term entry point for investors ahead of the 2028 compliance deadline.[16, 32]
ReposiTrak’s stock price has experienced a significant correction.[39, 40] The stock closed on June 30, 2026, at $9.00, down 2.28% for the session on a daily range of $8.83 to $9.10.[41] Over the past year, the stock has traded within a volatile range of $6.94 to $21.98 [24, 40], correcting more than 50% from its 52-week highs [40] due to the near-term revenue deceleration from the FSMA 204 extension.[6]
[13, 23]
▲
[42]
▲
[Current Price: $9.00][41]
▼
[39]
▼
[24, 40]
Source: SEC filings and Technical Database [13, 24, 39, 40, 41, 42]
The stock is currently trading approximately 20.03% below its 200-day Simple Moving Average (SMA), putting the long-term trend indicator around $11.49.[26] The 50-day SMA is at $9.79 (with a shorter-term support crossover at $9.48) [43], while the 20-day SMA is at $10.87.[43] This technical structure indicates that the stock remains in a medium-term bearish trend [26], although momentum indicators show signs of stabilization.[26, 40] The Relative Strength Index (RSI) stands at 45.27, representing a neutral-to-slightly-oversold stance.[26]
This technical view is supported by recent insider transactions.[36, 39] CEO Randall Fields directly owns 3,483,955 common shares and has executed small, prearranged Rule 10b5-1 sales to fulfill charitable commitments.[39, 44] This includes a sale of 4,000 shares on March 12, 2026, at an average price of $8.0599 [39], and earlier transactions of 8,000 shares in January 2026 at $10.93 [36] and 7,500 shares in March 2025 at $19.60.[44]
These small sales occurred near the recent $8.00 support level, which aligns with historical buying support.[39]
| Level Classification | Price Point ($) | Technical Significance |
|---|---|---|
| Major Resistance 2 | $13.75 | Repurchase price from Q2 fiscal 2026.[13, 23] |
| Major Resistance 1 | $10.00 - $10.60 | Multi-week consolidation range in June 2026.[42] |
| Current Stock Price | $9.00 | Closing price on June 30, 2026.[41] |
| Major Support 1 | $7.80 - $8.05 | Recent buyer support zone and insider transaction floor.[39] |
| Major Support 2 | $6.94 - $7.15 | 52-week absolute low.[24, 40] |
Source: SEC Form 4 and Stock Price Database [13, 24, 39, 40, 41, 42]
The short-term outlook suggests the stock will likely remain range-bound between $8.50 and $10.50 [42] until there is confirmation of accelerated contract wins or SPAR Group synergy validation.[4, 22] A sustained breakout above the $10.60 level, supported by above-average volume, would signal a potential trend reversal.[42, 45] This would shift the target toward the 200-day SMA near $11.49 and the key technical resistance level at $13.75.[13, 26]
View ReposiTrak, Inc. (TRAK) stock page
Loading the interactive version of this report…